Walvax Biotechnology Valuation

Q: What is the Fair Price of 300142 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

300142 (CN¥14.72) is trading above our estimate of [[fair value]] (CN¥0.28)

Is 300142 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300142 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300142 (CN¥14.72) is trading above our estimate of fair value (CN¥0.28)

Significantly Below Fair Value: 300142 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300142?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 300142. This is calculated by dividing 300142's market cap by their current preferred multiple.
What is 300142's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥23.54b

300142 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.8x
Enterprise Value/EBITDA	42.6x
PEG Ratio	3.3x

Price to Sales Ratio vs Peers

How does 300142's PS Ratio compare to its peers?

The above table shows the PS ratio for 300142 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7.1x
300601 Shenzhen Kangtai Biological Products	7.4x	24.7%	CN¥21.9b
300294 China Resources Boya Bio-pharmaceutical GroupLtd	9.1x	5.5%	CN¥18.3b
301301 Yili Chuanning BiotechnologyLtd	5.4x	11.0%	CN¥30.4b
000403 Pacific Shuanglin Bio-pharmacy	6.6x	15.0%	CN¥18.1b
300142 Walvax Biotechnology	7x	11.5%	CN¥23.5b

Price-To-Sales vs Peers: 300142 is good value based on its Price-To-Sales Ratio (7x) compared to the peer average (7.1x).

Price to Earnings Ratio vs Industry

How does 300142's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	38.5%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	38.5%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: 300142 is expensive based on its Price-To-Sales Ratio (7x) compared to the CN Biotechs industry average (7x).

Price to Sales Ratio vs Fair Ratio

What is 300142's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300142 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	7x
Fair PS Ratio	5.9x

Price-To-Sales vs Fair Ratio: 300142 is expensive based on its Price-To-Sales Ratio (7x) compared to the estimated Fair Price-To-Sales Ratio (5.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.